Phase II trial of aflibercept with FOLFIRI as a second‐line treatment for Japanese patients with metastatic colorectal cancer

Aflibercept targets vascular endothelial growth factor. The present study involved assessing the efficacy, safety and pharmacokinetics of aflibercept plus 5‐fluorouracil/levofolinate/irinotecan (FOLFIRI) as a second‐line treatment for metastatic colorectal cancer (mCRC) in Japanese patients. Afliber...

Descripción completa

Detalles Bibliográficos
Autores principales: Denda, Tadamichi, Sakai, Daisuke, Hamaguchi, Tetsuya, Sugimoto, Naotoshi, Ura, Takashi, Yamazaki, Kentaro, Fujii, Hirofumi, Kajiwara, Takeshi, Nakajima, Takako Eguchi, Takahashi, Shin, Otsu, Satoshi, Komatsu, Yoshito, Nagashima, Fumio, Moriwaki, Toshikazu, Esaki, Taito, Sato, Takeo, Itabashi, Michio, Oki, Eiji, Sasaki, Toru, Sunaga, Yoshinori, Ziti‐Ljajic, Samira, Brillac, Claire, Yoshino, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398889/
https://www.ncbi.nlm.nih.gov/pubmed/30657223
http://dx.doi.org/10.1111/cas.13943

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398889/
https://www.ncbi.nlm.nih.gov/pubmed/30657223
http://dx.doi.org/10.1111/cas.13943

Ejemplares similares